As of June 30, 2025, the Company’s principal subsidiaries are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Percentage |
|
|
|
|
|
|
|
|
of direct |
|
|
|
|
|
|
|
|
or indirect |
|
|
|
|
|
|
Date of |
|
ownership |
|
|
|
|
Place of |
|
incorporation or |
|
by the |
|
|
Subsidiaries |
|
incorporation |
|
acquisition |
|
Company |
|
Principal activities |
I-Mab Biopharma US Ltd. |
|
United States |
|
February 28, 2018 |
|
100% |
|
Research and development of innovative medicines |
I-Mab Biopharma Hong Kong Limited (“I-Mab Hong Kong”) |
|
Hong Kong |
|
July 8, 2016 |
|
100% |
|
Investment holding |
I-Mab Bio-tech (Tianjin) Co., Ltd. (“I-Mab Tianjin”) |
|
People’s Republic of China |
|
July 15, 2017 |
|
100% |
|
Research and development of innovative medicines |
|